Model of tumor dormancy/recurrence after short-term chemotherapy

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Li, Shenduo ^a   Kennedy, Margaret ^a   Payne, Sturgis ^a   Kennedy, Kelly ^a   Seewaldt, Victoria L ^a   Pizzo, Salvatore V ^a   Bachelder, Robin E ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; DOXORUBICIN; ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CELL CYCLE; CELL GROWTH; CELL PROLIFERATION; CELL SUBPOPULATION; COLONY FORMATION; CONTROLLED STUDY; DORMANCY; DRUG EXPOSURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; PROSTATE CANCER; TUMOR MODEL; BIOLOGICAL MODEL; DRUG EFFECTS; NEOPLASMS; PATHOLOGY; TIME; TUMOR CELL LINE; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; IN VITRO TECHNIQUES; MODELS, BIOLOGICAL; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; TIME FACTORS;

EID: 84901356000     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098021     Document Type: Article

References (14)

1. Weiss RB, Woolf SH, Demakos E, Holland JF, Berry DA, et al. (2003) Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 21: 1825-1835.
2. Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, et al. (2010) Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics. Journal of the National Cancer Institute 102: 1637-1652.
3. Puhr M, Hoefer J, Schafer G, Erb HH, Oh SJ, et al. (2012) Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. The American journal of pathology 181: 2188-2201.
4. Kuczynski EA, Sargent DJ, Grothey A, Kerbel RS (2013) Drug rechallenge and treatment beyond progression-implications for drug resistance. Nature reviews Clinical oncology 10: 571-587.
5. Moore N, Houghton J, Lyle S (2012) Slow-cycling therapy-resistant cancer cells. Stem cells and development 21: 1822-1830.
6. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, et al. (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80.
7. Fillmore CM, Kuperwasser C (2008) Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast cancer research: BCR 10: R25.
8. Iliopoulos D, Hirsch HA, Wang G, Struhl K (2011) Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proceedings of the National Academy of Sciences of the United States of America 108: 1397-1402.
9. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, et al. (2008) Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. Journal of the National Cancer Institute 100: 672-679.
10. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, et al. (2007) Molecular definition of breast tumor heterogeneity. Cancer cell 11: 259-273. (Pubitemid 46349843)
11. Lin WC, Rajbhandari N, Wagner KU (2014) Cancer Cell Dormancy in Novel Mouse Models for Reversible Pancreatic Cancer: A Lingering Challenge in the Development of Targeted Therapies. Cancer research 74: 2138-2143.
12. Brunsvig PF, Andersen A, Aamdal S, Kristensen V, Olsen H (2007) Pharmacokinetic analysis of two different docetaxel dose levels in patients with non-small cell lung cancer treated with docetaxel as monotherapy or with concurrent radiotherapy. BMC cancer 7: 197.
13. Liu J, Zheng H, Tang M, Ryu YC, Wang X (2008) A therapeutic dose of doxorubicin activates ubiquitin-proteasome system-mediated proteolysis by acting on both the ubiquitination apparatus and proteasome. American journal of physiology Heart and circulatory physiology 295: H2541-2550.
14. Williams KP, Allensworth JL, Ingram SM, Smith GR, Aldrich AJ, et al. (2013) Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and resensitization. Cancer letters 337: 77-89.